Diversity and function of regulatory T cells in health and autoimmune diseases
Journal of Autoimmunity,
Год журнала:
2025,
Номер
151, С. 103357 - 103357
Опубликована: Янв. 12, 2025
Язык: Английский
Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy
Annals of Clinical and Translational Neurology,
Год журнала:
2024,
Номер
11(10), С. 2657 - 2672
Опубликована: Сен. 15, 2024
Abstract
Objective
Anti‐CD20
therapy
is
a
highly
effective
treatment
for
multiple
sclerosis
(MS).
In
this
study,
we
investigated
MS‐related
changes
in
peripheral
blood
mononuclear
cell
(PBMC)
subsets
compared
to
healthy
controls
and
longitudinal
related
the
treatment.
Methods
Multicolor
spectral
flow
cytometry
analysis
was
performed
on
78
samples
characterize
disease‐
treatment‐related
PBMC
clusters.
Blood
from
MS
patients
were
collected
at
baseline
up
8
months
post‐treatment,
with
three
collection
points
after
initiation.
Unsupervised
clustering
tools
manual
gating
applied
identify
subclusters
of
interest
quantify
changes.
Results
B
cells
depleted
periphery
anti‐CD20
as
expected,
observed
an
isolated
acute,
transitory
drop
proportion
natural
killer
(NK)
NKT
among
main
populations
(
P
=
0.03,
0.004).
Major
affected
subpopulations
cytotoxic
immune
(NK,
NKT,
CD8
+
T
cells),
higher
reduced
brain‐homing
ability
regulatory
function
long‐term
anti‐CD20‐related
effect.
Additionally,
altered
distributions
memory
exhaustion
markers
both
CD4
cells.
Interpretation
The
findings
study
elucidate
phenotypic
clusters
NK
cells,
which
have
previously
been
underexplored
context
therapy.
Phenotypic
modifications
towards
more
controlled
phenotype
suggest
that
these
may
play
critical
unrecognized
role
mediating
therapeutic
efficacy
treatments.
Язык: Английский
Understanding Multiple Sclerosis Pathophysiology and Current Disease-Modifying Therapies: A Review of Unaddressed Aspects
Frontiers in Bioscience-Landmark,
Год журнала:
2024,
Номер
29(11)
Опубликована: Ноя. 19, 2024
Multiple
sclerosis
(MS)
is
a
complex
autoimmune
disorder
of
the
central
nervous
system
(CNS)
with
an
unknown
etiology
and
pathophysiology
that
not
completely
understood.
Although
great
strides
have
been
made
in
developing
disease-modifying
therapies
(DMTs)
significantly
improved
quality
life
for
MS
patients,
these
treatments
do
entirely
prevent
disease
progression
or
relapse.
Identifying
unaddressed
pathophysiological
aspects
targeted
to
fill
gaps
are
essential
providing
long-term
relief
patients.
Recent
research
has
uncovered
some
remain
outside
scope
available
DMTs,
as
such,
yield
only
limited
benefits.
Despite
most
being
by
many
patients
still
experience
relapse,
indicating
more
detailed
understanding
necessary.
Thus,
this
literature
review
seeks
explore
known
pathophysiology,
identify
present
explain
why
current
cannot
arrest
progression.
Язык: Английский